ArticlePloS one2014
Galectin-1 exerts inhibitory effects during DENV-1 infection.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 73 citations in OpenAlex.
- Article
- Galectin-3 disrupts tight junctions of airway epithelial cell monolayers by inducing expression and release of matrix metalloproteinases upon influenza A infection.Glycobiology · 2025Article
- Pilot proteomic analysis of immune dysregulation in dengue with prior SARS-CoV-2 infection.Frontiers in immunology · 2025Observational
- Galectin-1 Modulates the Fusogenic Activity of Placental Endogenous Retroviral Envelopes.Viruses · 2023Article
- Galectin-1: A Traditionally Immunosuppressive Protein Displays Context-Dependent Capacities.International journal of molecular sciences · 2023Review
- Article
- Molecular Identification and mRNA Expression Profiles of Galectin-9 Gene in Red Sea Bream (Animals : an open access journal from MDPI · 2021Article
- Utilization of Galectins by Pathogens for Infection.Frontiers in immunology · 2020Review
- Galectin-1 Ameliorates Influenza A H1N1pdm09 Virus-Induced Acute Lung Injury.Frontiers in microbiology · 2020Article
- Structure of the zebrafish galectin-1-L2 and model of its interaction with the infectious hematopoietic necrosis virus (IHNV) envelope glycoprotein.Glycobiology · 2019Article
- Restriction of Human Cytomegalovirus Infection by Galectin-9.Journal of virology · 2019Article
- Glycosylation-dependent galectin-receptor interactions promoteProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Chicken galectin-1B inhibits Newcastle disease virus adsorption and replication through binding to hemagglutinin-neuraminidase (HN) glycoprotein.The Journal of biological chemistry · 2017Article
- Functions of galectins as 'self/non-self'-recognition and effector factors.Pathogens and disease · 2017Review
- Secretion of Galectin-9 as a DAMP during Dengue Virus Infection in THP-1 Cells.International journal of molecular sciences · 2017Article
- Diet-Induced Nutritional Stress and Pathogen Interference in Wolbachia-Infected Aedes aegypti.PLoS neglected tropical diseases · 2016Article
- Serum Galectin-9 and Galectin-3-Binding Protein in Acute Dengue Virus Infection.International journal of molecular sciences · 2016Article
- The zebrafish galectins Drgal1-L2 and Drgal3-L1 bind in vitro to the infectious hematopoietic necrosis virus (IHNV) glycoprotein and reduce viral adhesion to fish epithelial cells.Developmental and comparative immunology · 2016Article
- mRNA Transcriptomics of Galectins Unveils Heterogeneous Organization in Mouse and Human Brain.Frontiers in molecular neuroscience · 2016Article
- Protective Effect of Galectin-1 duringMediators of inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV) is an enveloped RNA virus that is mosquito-transmitted and can infect a variety of immune and non-immune cells. Response to infection ranges from asymptomatic disease to a severe disorder known as dengue hemorrhagic fever. Despite efforts to control the disease, there are no effective treatments or vaccines. In our search for new antiviral compounds to combat infection by dengue virus type 1 (DENV-1), we investigated the role of galectin-1, a widely-expressed mammalian lectin with functions in cell-pathogen interactions and immunoregulatory properties. We found that DENV-1 infection of cells in vitro exhibited caused decreased expression of Gal-1 in several different human cell lines, suggesting that loss of Gal-1 is associated with virus production. In test of this hypothesis we found that exogenous addition of human recombinant Gal-1 (hrGal-1) inhibits the virus production in the three different cell types. This inhibitory effect was dependent on hrGal-1 dimerization and required its carbohydrate recognition domain. Importantly, the inhibition was specific for hrGal-1, since no effect was observed using recombinant human galectin-3. Interestingly, we found that hrGal-1 directly binds to dengue virus and acts, at least in part, during the early stages of DENV-1 infection, by inhibiting viral adsorption and its internalization to target cells. To test the in vivo role of Gal-1 in DENV infection, Gal-1-deficient-mice were used to demonstrate that the expression of endogenous Galectin-1 contributes to resistance of macrophages to in vitro-infection with DENV-1 and it is also important to physiological susceptibility of mice to in vivo infection with DENV-1. These results provide novel insights into the functions of Gal-1 in resistance to DENV infection and suggest that Gal-1 should be explored as a potential antiviral compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.